Book Online or Call 1-855-SAUSALITO

Sign In  |  Register  |  About Sausalito  |  Contact Us

Sausalito, CA
September 01, 2020 1:41pm
7-Day Forecast | Traffic

  • Search Hotels in Sausalito

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Gsk Plc ADR (NY: GSK )

33.70 +0.35 (+1.05%)
Official Closing Price Updated: 7:00 PM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Gsk Plc ADR

< Previous 1 2 3 4 5 6 7 8 9
...
35 36 Next >
Moderna Lost 27% Of Its Value Over Two Days. It Just Crumbled Again.
Moderna sustained a rare downgrade on Monday following its guidance cut for the year. 
Via Investor's Business Daily
Moderna Stock Trading Lower On Dismal Guidance, Analysts Cuts Price Targets Noting Competitive Pressure From GSK, Pfizer
Moderna cuts its 2024 sales forecast due to weaker demand for COVID-19 vaccines. Sales now expected between $3B-$3.5B, down from $4B. Analysts adjust price targets, citing competitive pressures from... 
Via Benzinga
Exposures COVID-19
US FDA expands Jemperli (dostarlimab-gxly) plus chemotherapy approval to all adult patients with primary advanced or recurrent endometrial cancer as the first and only immuno-oncology-based treatment to show an overall survival benefit
From GSK plc
Via Business Wire
British Pharma Giant GSK's Blockbuster Shingles And Respiratory Syncytial Virus Vaccine Q2 Sales Miss Expectations, Cuts Annual Vaccine Revenue Guidance
GSK reported Q2 sales of $9.95 billion, beating estimates of $9.66 billion. Specialty Medicine sales rose 20%, driven by strong HIV, Respiratory/Immunology, and Oncology performance. Core EPS of $1.10... 
Via Benzinga
Topics Earnings
Exposures Financial
Apple, Amazon, Microsoft, Meta Lead The Charge As Investors Bank On Tech Cheer For Rally's Reacceleration: Week Ahead In Earnings
The unfolding week's market trajectory depends on earnings from bellwether tech stocks and what the Fed has to say following its July meeting. 
Via Benzinga
Topics Economy
Exposures Interest Rates
Is GSK a Top-Value Stock Right Now?
GSK, a multinational pharma company, scans as a bargain. 
Via The Motley Fool
Tech Stocks On Track For Best Session In 5 Months Ahead Of Fed Meeting; Small Caps Target Highest Close Since January 2022: What's Driving Markets Wednesday?
Tech stocks soared to their best session in five months on Wednesday, ahead of the highly anticipated Federal Open Market Committee (FOMC) meeting. 
Via Benzinga
Topics Economy
Exposures Interest Rates
GSK Beats Second-Quarter Views, Raises Outlook; But Shares Fall On Shingrix Miss
The company, however, raised its sales and earnings outlook for the year. 
Via Investor's Business Daily
Wall Street Remains On Track For AMD-Led Rebound Ahead Of Fed Decision, Meta Earnings: Analyst Says 'The Bull Tends To Remain' Despite Near-Time Volatility
Tech optimism is likely to abound on Wall Street as AI-levered stocks are feeding off the strength generated by Advanced Micro Devices, Inc.‘s (NASDAQ:AMD) 
Via Benzinga
Topics Economy
Exposures Interest Rates
GSK Stock Earnings: GSK Beats EPS, Beats Revenue for Q2 2024
GSK stock results show that GSK beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
GSK's Top Selling Vaccine Can Potentially Reduce Dementia Risk, Research Suggests
New research suggests that GSK's Shingrix vaccine may reduce dementia risk, potentially revolutionizing treatment for older adults. The study, involving 200,000 people, indicates a significant... 
Via Benzinga
Pfizer And GSK's ViiV Healthcare's Two-Drug HIV Treatment Matches Gilead's Three-Drug Combo In Major Trial
ViiV Healthcare's Dovato matches Gilead's Biktarvy in effectiveness for HIV treatment. The study reveals Dovato's benefit of less weight gain compared to Biktarvy, highlighting its efficacy and patient... 
Via Benzinga
3 Stocks Under $10 With the Potential for Massive Gains
Discover the growth potential of top small-cap stocks in the consumer finance, healthcare equipment and pharmaceutical industries. 
Via InvestorPlace
Top Research Reports For Apple, Lowe's & Shopify
Today's Research Daily features new research reports on 16 major stocks, including Apple Inc., Lowe's Companies, Inc., and Shopify Inc., as well as two micro-cap stocks MIND Technology, Inc., and... 
Via Talk Markets
European Commission Faces Court Criticism Over COVID Vaccine Contract Transparency Ahead Of Vote on Ursula Von Der Leyen's Reappointment
European Commission faces scrutiny over COVID vaccine contract transparency ahead of key vote. Legal challenges and implications discussed. 
Via Benzinga
Exposures COVID-19
3 Top Cancer Treatment Stocks to Buy Now
These cancer treatment stocks are well-positioned to benefit tremendously from strong demand for their cancer treatments in the longer term. 
Via InvestorPlace
Positive News is Driving This Cancer Drug Maker’s Stock Higher
IDEAYA Biosciences stock is up more than 16% on positive treatment data in a Phase 2 clinical trial, but after a 76% run-up, IDYA stock may need a breather 
Via MarketBeat
The 3 Most Undervalued Pharma Stocks to Buy in July 2024
Pharma stocks can be great investments during times of growth and recession, and are made even better if the stock is undervalued. 
Via InvestorPlace
Topics Economy
Exposures Economy
GSK Begins Shipping Influenza Vaccine Doses for 2024-25 Season
From GSK plc
Via Business Wire
3 Dirt-Cheap Drug Developers With Blockbuster Potential
These are three of the best cheap drug developer stocks for investors to keep an eye as their growth could be imminent. 
Via InvestorPlace
Health Officials Keep Close Eye On Bird Flu As It Infects Cows For The First Time
Avian influenza continues to spread among animals and has infected four dairy workers in the US. Concerns about human-to-human transmission are low. 
Via Benzinga
The 3 Most Undervalued Under-$50 Stocks to Buy in July 2024
A full-throated bull market makes it tough to find undervalued stocks under $50, but these three could soon lead the charge higher. 
Via InvestorPlace
Pfizer's RSV Vaccine Abrysvo Clears Concerns Over Preterm Birth Risk, Safety For Pregnant Women, New Study Shows
Pfizer's RSV vaccine, Abrysvo, for pregnant women shows no increased risk of pre-term births, according to a study. Researchers found no significant difference in pre-term birth rates between... 
Via Benzinga
United Kingdom Stocks, ETFs To Watch After Keir Starmer, Labour Party Win
New leadership in the United Kingdom could make several sectors standout going forward. Here's what experts are saying after the election. 
Via Benzinga
Topics ETFs
Upcoming Stock Spinoffs: Should You Pounce or Pass?
Stock spinoffs are a unique opportunity to pick up unloved, unwanted businesses but patience is often needed before buying in. 
Via InvestorPlace
CureVac Layoffs 2024: What to Know About the Latest CVAC Job Cuts
CureVac layoffs are coming for 30% of the vaccine company's employees as it prepares for a restructuring that will save it over 30% in costs. 
Via InvestorPlace
Topics Workforce
Exposures Layoff
CVAC Stock Alert: CureVac Pops on Licensing Deal With GSK
CureVac stock is up on Wednesday as CVAC investors react to the company signing a new 1.4 billion euro licensing agreement with GSK. 
Via InvestorPlace
GSK Buys Full Rights To Investigational Covid-19 And Influenza Vaccines From CureVac For Around $1.5B
GSK and CureVac restructured their collaboration into a new licensing agreement, prioritizing mRNA vaccine development. GSK gains full control of vaccine candidates for influenza and COVID-19, while... 
Via Benzinga
Exposures COVID-19
3 No-Brainer Stocks to Buy With $300 Right Now for the Second Half of 2024
A modest amount of money can go a long way when it's put to work in highly innovative, game-changing businesses. 
Via The Motley Fool
Heartburn Drug Zantac Litigation: GSK And Other Pharma Giants Face Trial Over Cancer Claims
A Delaware judge dismissed GSK and other drugmakers' appeal, allowing over 70,000 lawsuits alleging Zantac causes cancer to proceed, with the companies needing Delaware Supreme Court approval to... 
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
< Previous 1 2 3 4 5 6 7 8 9
...
35 36 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Photos copyright by Jay Graham Photographer
Copyright © 2010-2020 Sausalito.com & California Media Partners, LLC. All rights reserved.